MHRA Has “Significant Failings” – UK Committee Report
This article was originally published in The Tan Sheet
Executive Summary
Britain's health authority needs an independent review to determine whether its current decision-making processes adequately reflect patients' health needs, the UK House of Commons Health Committee says
You may also be interested in...
Vioxx Hearing Witnesses Push For Independent Drug Safety Office
The proposal to create an independent Office of Drug Safety at FDA may be gaining momentum, following a congressional hearing reviewing FDA's handling of Merck's Vioxx (rofecoxib)
Bad Influence? U.K. Questions Pharma’s Sway On Health Care System
The U.K. House of Commons Health Committee will hold an "evidence session" Oct. 14 as part of an ongoing inquiry into the pharmaceutical industry's influence on the overall British healthcare system
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC